Entera Bio Ltd. Equity Repurchase (Common, Net)

Equity Repurchase (Common, Net) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Equity Repurchase (Common, Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Equity Repurchase (Common, Net) for the quarter ending June 29, 2020 was $0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Equity Repurchase (Common, Net) decreased by -100.0%
  • Annual Equity Repurchase (Common, Net) for 2019 was $12.8 Million (a 32.65% increase from previous year)
  • Twelve month Equity Repurchase (Common, Net) ending June 29, 2020 was $13.6 Million (a -0.19% decrease compared to previous quarter)
  • Twelve month trailing Equity Repurchase (Common, Net) increased by 37.95% year-over-year
Trailing Equity Repurchase (Common, Net) for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$13.6 Million $13.6 Million $12.8 Million $9.86 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Equity Repurchase (Common, Net) of Entera Bio Ltd.

Most recent Equity Repurchase (Common, Net)of ENTX including historical data for past 10 years.

Interactive Chart of Equity Repurchase (Common, Net) of Entera Bio Ltd.

Entera Bio Ltd. Equity Repurchase (Common, Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.0 $0.87
2019 $12.53 $0.21 $0.03 $12.77
2018 $0.0 $9.62 $9.62

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.